PCSK9 Inhibitors in Diabetic Dyslipidemia
(2019)
Book Chapter
(2019). PCSK9 Inhibitors in Diabetic Dyslipidemia. In RSSDI Diabetes Update 2018 (374-378). https://doi.org/10.5005/jp/books/18092_77
The association between cardiovascular disease (CVD) risk and raised serum total cholesterol (TC) and low density lipoprotein-cholesterol (LDL-C) has been demonstrated in epidemiology1 and intervention trials showing significant decreases in CVD foll... Read More about PCSK9 Inhibitors in Diabetic Dyslipidemia.